Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy

Huan Li, Shuanghui Yang, Ge Yu, Liangfang Shen, Jia Fan, Ling Xu, Hedong Zhang, Nianxi Zhao, Zihua Zeng, Ye Hu, Jianguo Wen, Youli Zu

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

The goal of precision therapy is to efficiently treat cancer without side effects. Aptamers are a class of small ligands composed of single-stranded oligonucleotides that bind to their targets with high affinity and specificity. In this study, we identified an ssDNA aptamer specifically targeting Maver-1 lymphoma cells with high binding affinity (Kd = 70±8 pmol/L). Interestingly, cellular cycle studies revealed that exposure of Maver-1 cells to synthetic aptamers triggered S-phase arrest of 40% of the cells (vs. 18% baseline). Confocal microscopy confirmed specific cell binding of aptamers and the resultant endocytosis into Maver-1 cells. Subsequent functional assays validated the fact that aptamer internalization into targeted cells is a prerequisite for Maver-1 cell growth inhibition. Importantly, aptamer-induced S-phase arrest induced enhanced chemotherapeutic results involving cytarabine, which primarily kills lymphoma cells at S-phase. Combination treatments revealed that aptamer re-exposure considerably primed Maver-1 cells for cytarabine chemotherapy, thus achieving a synergistic killing effect by reaching cell death rates as high as 61% (vs. 13% or 14% induced by aptamer or cytarabine treatment alone). These findings demonstrated that aptamers do not only act as molecular ligands but can also function as biotherapeutic agents by inducing S-phase arrest of lymphoma cells. In addition, logical combination of aptamer and cytarabine treatments ushers the way to a unique approach in precision lymphoma chemotherapy.

Original languageEnglish (US)
Pages (from-to)1204-1213
Number of pages10
JournalTheranostics
Volume7
Issue number5
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

    Fingerprint

Keywords

  • Aptamer
  • Biotherapeutics
  • Lymphoma
  • S-phase arrest
  • Synergistic chemotherapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Li, H., Yang, S., Yu, G., Shen, L., Fan, J., Xu, L., Zhang, H., Zhao, N., Zeng, Z., Hu, Y., Wen, J., & Zu, Y. (2017). Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy. Theranostics, 7(5), 1204-1213. https://doi.org/10.7150/thno.17069